Taiwan Bio Therapeutics Inc. (Taiwan Bio), founded in 2014 and headquartered in Hsinchu Science Park, Taiwan, is a clinical-stage biotechnology company specializing in regenerative medicine and cell therapies. The company develops novel cell-based treatments targeting degenerative diseases, cardiovascular conditions, diabetes complications, and autoimmune disorders.
Its pipeline includes mesenchymal stem cell (MSC) therapies such as Chondrochymal for knee osteoarthritis and Biochymal for non-healing wounds, alongside advanced programs like the regulatory T-cell (Treg) therapy TRK-001, currently in multicenter Phase 2 trials for preventing kidney transplant rejection. Taiwan Bio leverages proprietary platforms including FAST CGT for automated manufacturing and TDM (Therapeutics Design & Manufacturing) to provide CDMO/CMO services, enabling scalable production of MSCs, CAR-T, gene-modified cells, and Tregs.
Listed on the Taipei Exchange (6892.TWO), the firm collaborates with U.S. institutions, acquired TRACT Therapeutics to bolster its Treg portfolio, and recently partnered with Terumo Blood and Cell Technologies to automate TRK-001 manufacturing on the Quantum Flex system.
